A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

Phase 2 Completed 130 enrolled Eli Lilly and Company Incyte Corporation · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a dose ranging study to evaluate the safety and efficacy of baricitinib in the treatment of participants with mild to moderate diabetic kidney disease.

Timeline

Start: 2012-08
Primary completion: 2014-09
Completion: 2014-11

Publications

Hu S, Lee K, He JC, Fan Y. Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2026 Mar 10. doi: 10.2215/CJN.0000001053. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Baricitinib	Small molecule	0.5 mg	Oral
Subject	Baricitinib	Small molecule	0.75 mg	Oral
Subject	Baricitinib	Small molecule	1 mg	Oral
Subject	Baricitinib	Small molecule	1.5 mg	Oral
Subject	Baricitinib	Small molecule	2.75 mg	Oral
Subject	Baricitinib	Small molecule	4 mg	Oral

A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

Summary

Timeline

Publications

Drugs

Indications